Kyowa Kirin to Present Atopic Dermatitis Clinical Data from KHK4083/AMG 451 Phase 2 Study at The European Academy of Dermatology and Venereology 30th Congress
13.9.2021 16:00:00 EEST | Business Wire | Press release
Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) , a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced detailed data from a Phase 2 study of KHK4083/AMG 451 will be highlighted in late-breaking oral presentation at the European Academy of Dermatology and Venereology 30th Virtual Congress to be held September 29 – October 2, 2021. KHK4083/AMG 451 is a potential first-in-class anti-OX40 fully human monoclonal antibody in development for the treatment of atopic dermatitis, with potential in other autoimmune diseases.
Presentation Title:
Efficacy and safety results of KHK4083/AMG 451 (anti-OX40 mAb) in subjects with moderate to severe atopic dermatitis: a phase 2, multicentre, randomized, double-blind, parallel-group, placebo-controlled study
Submission Topic: 5. Atopic Dermatitis/Eczema
Session date and time: Saturday 2 October 2021, 10.00 - 11.00(CEST)
Primary Author: Emma Guttman-Yassky, M.D./Ph.D., System Chair for the Department of Dermatology and Waldman Professor of Dermatology and Immunology, Icahn School of Medicine at Mount Sinai and Director of the Center for Excellence in Eczema, and the Laboratory of Inflammatory Skin Diseases at Mount Sinai.
The abstract will be available on the EADV Congress website.
The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
About KHK4083/AMG 451
KHK4083/AMG 451 is an anti-OX40 fully human monoclonal antibody engineered with Kyowa Kirin’s patented POTELLIGENT® defucosylation technology to enhance its antibody-dependent cellular cytotoxicity (ADCC) activity. The initial KHK4083/AMG 451 antibody was discovered in collaboration between Kyowa Kirin US Research and La Jolla Institute for Immunology.
KHK4083/AMG 451 targets and inhibits the activity of the OX40 receptor expressed on the surface of effector T-cells, and has been shown to deplete activated OX40+ T-cells by ADCC. It has been reported that effector T cells expressing OX40 are present in the lesions of patients with atopic dermatitis and are critical in their development. Kyowa Kirin antibodies powered by POTELLIGENT technology with ADCC activity are currently marketed in several other therapeutic areas, including Oncology and Asthma. This potent antibody-enhancement platform is also licensed to numerous third parties throughout the biopharmaceutical industry.
On June 1, 2021, Kyowa Kirin entered into an agreement with Amgen (NASDAQ: AMGN) to jointly develop and commercialize KHK4083/AMG 451. Under the terms of the agreement, Amgen will lead the development, manufacturing, and commercialization for KHK4083/AMG 451 for all markets globally, except Japan, where Kyowa Kirin will retain all rights. If approved, the companies will co-commercialize the asset in the United States and Kyowa Kirin has opt-in rights to co-promote in certain other markets including Europe and Asia.
An overview of the KHK4083/AMG 451 Phase 2 Study
A Phase 2, multicenter, randomized, double-blind, and placebo-controlled clinical study (NCT03703102) was conducted in the U.S., Japan, Canada, and Germany to investigate the efficacy and safety of KHK4083/AMG 451. The study included 274 patients with moderate-to-severe atopic dermatitis, who were not adequately controlled with topical agents. The primary endpoint of the study was "percent change from baseline in Eczema Area and Severity Index (EASI) 1 at 16 weeks”.
About OX40
OX40 is a co-stimulatory molecule and a member of the tumor necrosis factor receptor (TNFR) superfamily. It has been reported that activated effector T cells express OX402,3 and are present in the lesions of patients with atopic dermatitis4. Professor Michael Croft, Ph.D., who is Director, Scientific Affairs, La Jolla Institute for Immunology helped identify that OX40 plays an important role in T cell proliferation, survival and formation of memory T cells5.
About Kyowa Kirin
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, we apply cutting-edge science including expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com/.
Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.
References
- Hanifin JM.; Thurston M.; Omoto M.; Cherill R.; Tofte SJ.; Graeber M: The eczema area and severity index（EAS）: assessment of reliability in atopic dermatitis. EASI Evaluator Group: Exp Dermatol, 2001; 10: 11-18.
- Croft, M.; So, T.; Duan, W.; Soroosh, P.: The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol: Rev. 2009, 229, 173–191.
- Croft, M. Control of Immunity by the TNFR-Related Molecule OX40 (CD134): Annu. Rev. Immunol. 2010, 28, 57–78.
- Masutaka F.; Mihoko F. OX40L–OX40 Signaling in Atopic Dermatitis: J. Clin. Med. 2021, 10, 2578
- Gramaglia I; Jember A; Pippig SD; Weinberg AD, Killeen N; Croft M: The OX40 Costimulatory Receptor Determines the Development of CD4 Memory by Regulating Primary Clonal Expansion: J Immunol 2000: 165 (6) 3043-50; DOI: 10.4049/jimmunol.165.6.3043
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005356/en/
Contact information
Hiroki Nakamura (Global, Japan), +81-3-5205-7205
Lauren Walrath (North America), +1-646-526-4454
Stacey Minton (EMEA), +44 (0) 7769 65607
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tacton Named a Leader in the 2026 Gartner® Magic Quadrant™ for CPQ Applications for the Fourth Consecutive Year27.1.2026 19:00:00 EET | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex, configurable products, today announced that it has been named a Leader in the 2026 Gartner® Magic Quadrant™ for CPQ Applications. This marks the fourth consecutive year Tacton has been recognized as a Leader in the report. Among the 16 vendors evaluated, Tacton placed highest in the quadrant on Completeness of Vision and for the second consecutive year is positioned highest in Ability to Execute. Tacton CPQ is designed to support manufacturers selling highly configurable products by helping them: Ensure accurate configuration so every quote reflects valid options and constraints Quote faster with confidence across high-variance portfolios without relying on manual engineering checks Maintain pricing and margin control through consistent configuration and pricing logic This approach supports manufacturers as they manage complexity while meeting buyer expectations for speed and accuracy. “We
CSG Recognized in Multi-Category Trusted Analyst Reports for CPQ, Monetization, and Digital Partner Management27.1.2026 18:05:00 EET | Press release
Communication service providers (CSPs) are under pressure to simplify complexity, monetize new services, and deliver experiences customers trust with speed and accuracy. To succeed, they need partners who can turn quote-to-cash and digital monetization into a competitive advantage, not just a back-office function. Over the past year, CSG® (NASDAQ: CSGS) has achieved multi-category recognition from leading analyst firms for doing exactly that. To CSG, these recognitions reinforce a role as a go-to partner for CSPs looking to move faster, unlock new revenue streams, and modernize their core with AI-powered, telco-specific platforms built for real-world complexity. CPQ Leadership for Complex B2B and B2B2X Monetization CSG Quote & Order continues to stand out for CSPs that need to configure complex offers, quote with confidence, and move from deal to revenue without friction. With Quote & Order, CSG is named: A Challenger in the 2026 Gartner® Magic Quadrant™ for Configure, Price & Quote Ap
ThetaRay Unveils Ray: An Agentic AI Investigation Suite Delivering Faster, More Consistent AML Investigations27.1.2026 18:00:00 EET | Press release
In the face of rapidly evolving global regulatory standards and rising Anti-Money Laundering (AML) scrutiny, ThetaRay today announced the launch of Ray, an Agentic AI AML investigation suite designed to transform how financial institutions conduct transaction monitoring investigations. Embedded in the ThetaRay Investigation Center, Ray extends Cognitive AI from detection to investigation, combining autonomous investigative execution with on-demand analyst support enabling financial institutions to significantly improve case resolution time and bring greater consistency to the investigation process across teams and jurisdictions. Global regulators are converging on higher expectations for investigative quality and documentation. In the European Union, the new Anti-Money Laundering Regulation (AMLR) and the broader AML Authority framework, created a unified rulebook requiring stronger due diligence, more rigorous monitoring and record-keeping, and consistent compliance controls across ju
State Street, in Collaboration with ADIO, to Create 300+ New Jobs With Launch of New Al Ain Operations Hub27.1.2026 17:15:00 EET | Press release
State Street Corporation (NYSE: STT), one of the world’s leading providers of financial services to institutional investors, has signed a support agreement with the Abu Dhabi Investment Office (ADIO) to establish a new operating center in the Al Ain region, Abu Dhabi. The collaboration marks a significant step in State Street’s long-term expansion strategy in the Middle East and UAE and reinforces its role as a strategic partner within the Abu Dhabi Global Market (ADGM) ecosystem. As part of its long-term growth plan in Abu Dhabi and aligning to State Street’s global clients’ increasing presence in Abu Dhabi, the new operating hub will create more than 300 financial services roles over the next four years, providing meaningful career pathways for local Emirati talent. In addition, State Street will collaborate with local universities to create career and internship opportunities for graduates, as well as organize training and seminars to help develop the next generation of local young
Andersen Consulting Strengthens Cybersecurity Capabilities with Addition of RedLegg27.1.2026 16:30:00 EET | Press release
Andersen Consulting deepens its cybersecurity offering through a Collaboration Agreement with RedLegg, a cybersecurity firm known for its managed threat detection and advisory services. Founded in 2008 and headquartered in the U.S., RedLegg delivers tailored cybersecurity solutions with a focus on risk mitigation, managed security services, and penetration testing. Its offerings include managed detection and response (MDR), incident response, policy development, and virtual CISO advisory. Serving mid-market clients across finance, insurance, legal, and healthcare, RedLegg combines automation, threat intelligence, and a dedicated Security Operations Center (SOC) to help organizations streamline cybersecurity operations and build long-term resilience. “Our focus has always been on helping clients cut through the noise and prioritize what truly matters — building defenses that actually perform,” said Lynn Weddle, president of RedLegg. “Collaborating with Andersen Consulting expands our ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom